Susan Margulies is an American engineer and assistant director of the U.S. National Science Foundation, heading the Directorate for Engineering.[1] She is also the Georgia Research Alliance Eminent Scholar in Injury Biomechanics and Professor in the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University, where she served as chair from 2017 to 2021.[2] She is a world leader in the biomechanics of head injury in infants.
After completing her PhD, Margulies joined the Mayo Clinic as a postdoctoral researcher working in a pulmonary lab.[5] In 1993 she joined University of Pennsylvania.[7] She was the first woman to be appointed Professor to the Biomedical engineering department at the University of Pennsylvania in 2004.[5] Here she led the Injury Biomechanics lab, focussing on lung injury and head injury.[8] The lung research studied lung function in vivo and in vitro using animal models developed for pulmonary diseases.[9] Her head injury research integrated animal models, computational models, patient data and mechanical properties in order to understand children's traumatic brain injury.[9] She is interested in the injury thresholds within the brain and lung.[7] She launched the Neurointensive Care and Assessment Facility with money from National Institutes of Health.[10] By studying the molecular biology of injured cells, Margulies hopes to develop therapeutic measures for traumatic injury.[11][12]
In 2015 she joined the advisory board of Astrocyte Pharmaceuticals.[13] In May 2017 she was announced as Chair of the Coulter Department and Eminent Scholar at Emory University and the Georgia Institute of Technology.[14] She has received over $35 million in research funding, published over 350 peer-reviewed scientific articles and 11 book chapters.[15][16]
In 2020 Margulies was elected to the National Academy of Engineering for elaborating the traumatic injury thresholds of brain and lung in terms of structure-function mechanisms.[17] The same year she was also elected to the National Academy of Medicine for identifying how and why injuries occur in children's brains and lungs through the development and use of novel platform technologies and models, and for translating basic discoveries of three therapies in pre-clinical trials.[18]